Page 2 - Initial Treatment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Civil servants have been told to work from home after offices used by government departments including a health agency became infested with bedbugs.

(Reuters) -Gilead Sciences said on Monday its drug, Trodelvy, failed to significantly improve survival for previously treated patients with advanced non-small cell lung cancer (NSCLC) in a late-stage study, sending its shares down more than 10%. The California-based drugmaker was testing Trodelvy, which belongs to a class of treatments known as antibody drug conjugates, in patients with both squamous and non-squamous NSCLC - the most common type of lung cancer. Roughly 230,000 adults in the United States were estimated to be diagnosed with lung cancer in 2023, and NSCLC accounts for 81% of a...

/PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its PulseSelect™ Pulsed Field Ablation (PFA) System...

- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib

(NewsUSA) - Pulse Check: 3 Things You May Not Know About the Most Common Heart Rhythm Disorder